-+ 0.00%
-+ 0.00%
-+ 0.00%

Sarepta Therapeutics announces preliminary Phase 1/2 data for SRP-1001 and SRP-1003; dose escalation continues with no dose-related safety signals observed to date

Reuters·03/25/2026 13:34:45

Please log in to view news